



Press Release

**Claris receives Supplemental ANDA approval for Fluconazole Injection in 50 ml PVC Bags
Claris will be only company offering Fluconazole Injection USP in 50 ml PVC bags in the US.**

Ahmedabad, India, April 21, 2015: Claris Lifesciences Limited (Claris) announced today that it has received the Supplemental Abbreviated New Drug Application (ANDA) approval for Fluconazole Injection in the United States of America (US). Claris currently marketing Fluconazole in 2 mg/ml formulation packed in 100 ml and 200 ml PVC Bags and now with the approval of supplemental ANDA, Claris is the only company to be able to sell Fluconazole in 50 ml variant in the US. By launching this variant Claris will be addressing the need of the medical fraternity.

Claris is one of the few injectables companies from India to have its own front end in the US, the Company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The Company has 13 ANDAs approved in its name across 8 molecules. The Company has a under registration pipeline of 25 ANDAs across 22 molecules having an estimated addressable market size of USD 2.2 Bn.

###

Disclaimer

This press release may include "forward-looking statements" which involve a number of risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future. Claris Lifesciences Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Market information mentioned in the press release is based on IMS Data (June 2013) and/or internal estimates of the company.

About Claris Lifesciences Limited

Claris Lifesciences Limited (BSE Code: 533288) is the holding company with three segmental revenues (i) the Speciality Injectables Business which is housed in a wholly owned subsidiary; Claris Injectables Limited, (ii) 20% stake in the Joint Venture with Otsuka and Mitsui for the Infusion Business in India and Emerging Markets, and (iii) the Treasury and Cash management for the funds in the HoldCo.

For more information about the company, log on to: www.clarislifesciences.com

About Claris Lifesciences Inc.

Claris Lifesciences Inc. is a pure play injectables company, involved in marketing and distribution of generic injectables in United States. The company is a wholly-owned subsidiary of Claris Lifesciences Ltd. Headquartered in New Jersey, USA, Claris Inc. has full-fledged presence to cater to the growing and unmet demands of hospitals and medical professionals for injectable products. Clairs Inc. has full-fledged sales, marketing and regulatory capabilities established to ensure seamless product availability and after-sales services and to ensure customer delight at every step of value chain.

With 8 molecules across 13 ANDAs and a growing portfolio, Claris Inc. is one of a few players to have launched technologically-advanced and complex-to-manufacture products in premix bags both PVC and non-PVC materials. The other technological platforms include glass vials and ampoules. Having established a strong team to address customer needs personally and provide prompt & satisfactory services, the company places major emphasis on quality and technology of products, which are manufactured at cGMP compliant facilities inspected by FDA.

For more information about the company, log on to: <http://www.us.clarislifesciences.com>

Claris Lifesciences Limited

Claris Corporate Headquarters, Nr. Parimal Rly. Crossing,
Ellisbridge, Ahmedabad 380 006, India.
Tel: +91-79-26563331, 66309339 Fax: +91-79-26408053
www.clarislifesciences.com

(Corporate Identity Number: L85110GJ1994PLC022543)